Cizutamig

Phase 1Small molecule

Cizutamig is one of 101 small molecule programs targeting Systemic Lupus Erythematosus (SLE). It is currently in Phase 1.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus Erythematosus (SLE)Recruiting

Generalized Myasthenia GravisRecruiting

Rheumatoid ArthritisRecruiting

Ulcerative ColitisNot yet recruiting

Systemic Lupus Erythematosus (SLE)Phase 1

Recruiting

Generalized Myasthenia GravisPhase 1

Recruiting

Rheumatoid ArthritisPhase 1

Recruiting

Ulcerative ColitisPhase 1

Not yet recruiting

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Actos

Takeda

Preclinical

2 2

Celexa

AbbVie

Preclinical

1 3

Voltaren

Cataflam

Plaquenil

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Cizutamig

CCandid Therapeutics

Phase 1

1 10

Pneumococcal Conjugate Vaccine

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Rheumatoid Arthritis

NCT06946199

Q4 2027

Phase 1Not yet recruiting

Ulcerative Colitis

NCT07353450

Q2 2028

Phase 1Recruiting

Generalized Myasthenia Gravis

NCT07215650

Phase 1Recruiting

Systemic Lupus Erythematosus (SLE)

NCT07215663

Clinical

Trials by Indication[1]

Ulcerative Colitis1 trial

A Study of Cizutamig for Patients With Ulcerative Colitis

Not yet recruiting·RRuijin Hospital·Phase 1·NCT07353450·15 enrolled

Rheumatoid Arthritis1 trial

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06946199·28 enrolled

Generalized Myasthenia Gravis1 trial

A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Clinical Activity of Cizutamig in Patients With Generalized Myasthenia Gravis (gMG)

Recruiting·CCandid Therapeutics·Phase 1·NCT07215650·44 enrolled

Systemic Lupus Erythematosus (SLE)1 trial

Recruiting·CCandid Therapeutics·Phase 1·NCT07215663·47 enrolled

Hypersensitivity1 trial

A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases

Withdrawn·CCandid Therapeutics·Phase 1·NCT07408869

1 more indication

Unspecified1 trial

A Randomized, Double-blind, Phase 1 Study to Evaluate the Absolute Bioavailability of Cizutamig Following Single Intravenous or Subcutaneous Administration in Healthy Adult Participants

Completed·CCandid Therapeutics·Phase 1·NCT07236411·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Cizutamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cizutamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cizutamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Candid Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCandid Therapeutics

Cizutamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Ulcerative Colitis1 trial

Rheumatoid Arthritis1 trial

Generalized Myasthenia Gravis1 trial

Systemic Lupus Erythematosus (SLE)1 trial

Hypersensitivity1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News